PROCÉDÉ DE DÉPISTAGE D'UN MÉDICAMENT ANTICANCÉREUX INHIBANT LA LIAISON DE LA MÉTHIONYL-ARNT SYNTHÉTASE (MRS) DE ET LA KINASE DÉPENDANTE À LA CYCLINE 4 (CDK4)
MEDICINAL BIOCONVERGENCE RESEARCH CENTER;재단법인 의약바이오컨버젼스연구단
发明人:
KWON, Nam Hoon,권남훈,LEE, Jin Young,이진영,KIM, Sunghoon,김성훈
申请号：
KRKR2016/004163
公开号：
WO2017/082494A1
申请日:
2016.04.21
申请国别(地区):
KR
年份:
2017
代理人:
摘要：
The present invention relates to a method for screening for an anticancer drug inhibiting the binding of methionyl-tRNA synthetase (MRS) and cyclin-dependent kinase 4 (CDK4) and, more specifically, to: a method for screening for an anticancer drug； and an anticancer composition containing, as an active ingredient, an anticancer drug selected by the method, which comprises the steps of: making MRS or a fragment thereof come into contact with CDK4 or a fragment thereof in the presence or absence of a test material； measuring the binding of MRS and CDK4； determining a change, caused by the test material, in the level of binding of MRS and CDK4； selecting a test material reducing the level of binding of MRS and CDK4； and checking the anticancer activity of the selected test material in cells or animals. The present invention can be useful for developing an anticancer drug, having a completely new mechanism, on the basis of the discovery that MRS is a novel CDK4 regulator stabilizing CDK4, which is important in cancer incidence and progression, by directly binding thereto. In addition, an anticancer composition containing, as an active ingredient, an anticancer drug selected by the method of the present invention can be useful for developing an anticancer drug, which can lower CDK4 protein level by inhibiting the expression of MRS or inhibiting the binding of MRS and CDK4, can effectively block cancer progression, and particularly, does not express ρ16INKa.La présente invention concerne un procédé de dépistage d'un médicament anticancéreux inhibant la liaison de la méthionyl-ARNt synthétase (MRS) de et la kinase dépendante à la cycline 4 (CDK4), et plus particulièrement : un procédé de dépistage d'un médicament anticancéreux； et une composition anticancéreuse contenant, comme principe actif, un médicament anticancéreux choisi par le procédé, qui comprend les étapes consistant : à amener la MRS ou un fragment de cette dernière à venir en contact avec la CDK4 ou un fragmen
